Gemtuzumab ozogamicin (GO) is one such treatment where calicheamicin is conjugated to an anti-CD33 antibody and has potent anti-tumor effects on CD33-expressing cells, found in a majority of AML cases [45, 46]. The gene discussed is CD33; the disease is acute myeloid leukemia.